Real-World Evidence on Prescribing Patterns and Lipid-Lowering Effectiveness of Monoclonal Antibody PCSK9 Inhibitors from Hong Kong

Eur J Prev Cardiol. 2026 Feb 24:zwag122. doi: 10.1093/eurjpc/zwag122. Online ahead of print.

Bingbing Zhu¹, Yuexi Liao¹, Qiuyan Yu¹, David Tak Wai Lui², Emmanuel Chun-Ka Wong^{3

4

5}, Esther W Y Chan¹, Celine S L Chui⁶, Joseph Edgar Blais¹

¹ Centre for Safe Medication Practice and Research, Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.
² Division of Endocrinology and Metabolism, Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.
³ Cardiology Division, Department of Medicine, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.
⁴ Cambridge Stem Cell Institute, The University of Cambridge, Cambridge, United Kingdom.
⁵ Cardiac and Vascular Center, The University of Hong Kong Shenzhen Hospital, Shenzhen, Guangdong Province, China.
⁶ School of Nursing, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong SAR, China.

No abstract available